Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers |
| |
| Authors: | Maher S Saifo,Donald R Rempinski Suffix" >Jr,Youcef M Rustum,Rami G Azrak |
| |
| Affiliation: | 1.Department of Cancer Biology,Roswell Park Cancer Institute,Buffalo,USA;2.Department of Oncology,Albairouni University Hospital, Damascus University,Damascus,Syria |
| |
| Abstract: | Background Beta-catenin is a multifunctional oncogenic protein that contributes fundamentally to cell development and biology. Elevation in expression and activity of β-catenin has been implicated in many cancers and associated with poor prognosis. Beta-catenin is degraded in the cytoplasm by glycogen synthase kinase 3 beta (GSK-3β) through phosphorylation. Cell growth and proliferation is associated with β-catenin translocation from the cytoplasm into the nucleus. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
